Korean J Pediatr Hematol Oncol.  1999 Apr;6(1):39-47.

Expression of Multidrug Resistance (MDR) Associated P-glycoprotein of Acute Lymphoblastic Leukemia in Children

• Choi YJ
• U CU
• Lee JH
• Lee KC
• Kim SK
• Park SE

Abstract

PURPOSE: To evaluate the association between multidrug resistance (MDR) gene and prognosis of acute lymphoblastic leukemia (ALL), several parameters were compared according to the expression status of MDR associated P-glycoprotein.
METHODS
40 bone marrow samples from 36 children of acute lymphoblastic leukemia were analyzed with immunohistochemical stain by C219 monoclonal antibody.
RESULTS
1) The expression of MDR associated P-glycoprotein was positive in 47% at the time of initial diagnosis & 66.7% at relapse. 2) There are no stastical difference between two groups in complete remission rate, relapse rate, mean 2 years survival rate. 3) Event free survival duration was 11.3 months (+/-8.5 months) in P-glycoprotein positive group, while 20 months (+/-7.3months) in P-glycoprotein negative group (P<0.05). 4) There are no stastical difference between two groups in the mean age, sex ratio, initial WBC and immunophenotype of subjects.
CONCLUSION
These results suggested the possibility of adopting MDR associated P-glycoprotein in the design of therapeutic regimen and prognostification of childhood acute lymphoblastic leukemia. However, a prospective, randomized study incorporating a larger population should precede before a firm conclusion of significance would draw regarding the prognostic and the therapeutic implication of P-glycoprotein in childhood acute lymphoblastic leukemia.

Keyword

Acute lymphoblastic leukemia; Multidrug resistance associated P-glycoprotein

MeSH Terms

Bone Marrow
Child*
Diagnosis
Disease-Free Survival
Drug Resistance, Multiple*
Humans
P-Glycoprotein*
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Prognosis
Prospective Studies
Recurrence
Sex Ratio
Survival Rate
P-Glycoprotein